Department of Surgery, Yokohama City University, Yokohama, Japan;
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
In Vivo. 2022 Jan-Feb;36(1):482-489. doi: 10.21873/invivo.12728.
BACKGROUND/AIM: We investigated the association of the preoperative lymphocyte-to-C-reactive-protein ratio (LCR) with gastric cancer survival and recurrence after curative treatment.
This study included 480 patients who underwent curative surgery followed by adjuvant treatment for gastric cancer between 2013 and 2017. The prognostic factors for overall survival (OS) and recurrence-free survival (RFS) were identified.
A LCR of 7,000 was regarded as the optimal critical point of classification, considering the 1-, 3- and 5-year survival rates. The OS rates at 3 and 5 years after surgery were 84.4% and 73.9% in the low-LCR group, respectively, and 92.4% and 87.0% in the high-LCR group, respectively, and were statistically significantly different. The RFS rates at 3 and 5 years after surgery were 78.8% and 68.7% in the low-LCR group, respectively, and 89.3% and 86.6% in the high-LCR group, respectively, with a statistically significant difference. A multivariate analysis showed that the LCR was a significant independent prognostic factor for both OS and RFS.
The LCR was a significant prognostic factor for survival in patients who underwent curative treatment for gastric cancer.
背景/目的：我们研究了术前淋巴细胞与 C 反应蛋白比值（LCR）与胃癌根治性治疗后生存和复发的关系。
本研究纳入了 2013 年至 2017 年间接受根治性手术及辅助治疗的 480 例胃癌患者。确定了总生存（OS）和无复发生存（RFS）的预后因素。
考虑到 1、3 和 5 年的生存率，LCR 为 7000 被认为是最佳分类临界点。术后 3 年和 5 年的 OS 率分别为低 LCR 组的 84.4%和 73.9%，高 LCR 组的 92.4%和 87.0%，差异有统计学意义。术后 3 年和 5 年的 RFS 率分别为低 LCR 组的 78.8%和 68.7%，高 LCR 组的 89.3%和 86.6%，差异有统计学意义。多因素分析显示，LCR 是 OS 和 RFS 的独立预后因素。
LCR 是胃癌根治性治疗后患者生存的重要预后因素。
